Archynetys Live news trend intelligence
◼ Archived Business 🔮 Archynetys predicts: fades by tomorrow — graded ✓ correct

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026

Eli Lilly's Jaypirca has received a positive CHMP recommendation for the treatment of chronic lymphocytic leukemia (CLL) in the European Union.

11sources
15articles
12velocity
+0%since first seen
25d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

📍 How it ended

The CHMP recommended pirtobrutinib for EU approval in CLL across all lines of therapy. This positive EMA opinion for Jaypirca contributed to a rise in Eli Lilly shares.

Epilogue added 15d ago, after coverage quieted.

The brief

The Committee for Medicinal Products for Human Use (CHMP) met from June 22-25, 2026, resulting in a recommendation for the approval of Eli Lilly's Jaypirca (pirtobrutinib). The drug is intended for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy.

Coverage from Yahoo Finance, GuruFocus, and the European Medicines Agency emphasizes that the marketing authorization application has been submitted to the European Commission. Following these developments, Eli Lilly shares rose over 4%, according to 富途牛牛.

Further developments include the examination of Phase 3 results from the BRUIN CLL-322 trial and exploration of treatment-free remissions with pirtobrutinib, as noted by Oncodaily and Targeted Oncology.

Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 25d ago.

Quick answers

What is Jaypirca?

Jaypirca (pirtobrutinib) is a treatment for adults with chronic lymphocytic leukemia (CLL).

Which regulatory body recommended the approval?

The Committee for Medicinal Products for Human Use (CHMP) provided the recommendation.

What was the market reaction for Eli Lilly?

According to 富途牛牛, Eli Lilly and Co (LLY.US) shares rose over 4%.

Coverage (15)

Topics

Eli Lilly CHMP Jaypirca CLL EMA

Related trends